Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

Delayed allograft rejection by the suppression of class II transactivator.

Experimental & molecular medicine - 30 Jun 2006

Kim Tae Woon, Choi Young Mi, Seo Jae Nam, Kim Ju Hyun, Suh Young Ho, Chung Doo Hyun, Jung Kyeong Cheon, Oh Kwon Ik

Abstract excerpt

(CIITA) down-modulation on allograft rejection. To inhibit the function of CIITA, we constructed a series of CIITA mutants and found one exhibiting the dominant-negative effect on the regulation of major histocompatibility complex (MHC) class II expression. To test whether the CIITA dominant-negative mutant reduces immunogenicity, CIITA-transfected melanoma cells were injected into allogeneic host and assessed...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Genes, MHC Class II
Share to Graft Rejection

Methodology Data sources Editorial policy Privacy Delete account & data About Contact Helena Bioinformatics

Share to Graft Survival

Share to Histocompatibility Antigens Class II

Share to Interferon-gamma

Share to Melanoma, Experimental

Share to Skin Transplantation

Share to Transplantation, Homologous

Source

Identifiers

PMID: 16819279
DOI: 10.1038/emm.2006.26

Genes

CIITA

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

Delayed allograft rejection by the suppression of class II transactivator.PMID 16819279Read ↗

CIITA-induced MHC class II expression in mammary adenocarcinoma leads to a Th1 polarization of the tumor microenvironment, tumor rejection, and specific antitumor memory.Semantic proximity Read ↗

Loss of tumor cell MHC class II drives MAPK inhibitor insensitivity of BRAF-mutant anaplastic thyroid cancers.Semantic proximity Read ↗

Invariant chain+ N2a neuroblastoma cells stably expressing the class II MHC transactivator CIITA fail to stimulate anti-tumor immunity.Semantic proximity Read ↗

Alloreactive T cells that do not require TCR and CD8 coengagement are present in naive mice and contribute to graft rejection.Semantic proximity Read ↗

Engineered regulatory T cells coexpressing MHC class II:peptide complexes are efficient inhibitors of autoimmune T cell function and prevent the development of autoimmune arthritis.Semantic proximity Read ↗

Induction of MHC class I expression by the MHC class II transactivator CIITA.Semantic proximity Read ↗

MHC class II-deficient tumor cell lines with a defective expression of the class II transactivator.Semantic proximity Read ↗

Major histocompatibility complex class II-transfected tumor cells present endogenous antigen and are potent inducers of tumor-specific immunitySemantic proximity Read ↗

Invariant chain alters the malignant phenotype of MHC class II+ tumor cells.Semantic proximity Read ↗

Generating MHC Class II+/Ii- phenotype after adenoviral delivery of both an expressible gene for MHC Class II inducer and an antisense Ii-RNA construct in tumor cells.Semantic proximity Read ↗

Transplantation effects of a unique major histocompatibility complex class I mutation.Semantic proximity Read ↗

[Construction of mutants of MHC class II molecule transactivator gene capable of suppressing HLA-DR/DQ expression and exploration on their mechanism].Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.